Acorda公司研发的钾通道阻滞剂dalfampridine缓释片(商品名:Ampyra)于2010年1月获美国FDA批准用于改善多发性硬化症(MS)患者的行走能力。这是首个获准用于该用途的药物,其能提高受损神经的传导功能,但确切作用机制尚不明确。Acorda公司近日在第63届美国神经病学学会年会上公布的最新数据显示,不管MS患者治疗前行走速度和MS相关的总体残疾程度如何 Acorda’s potassium channel blocker, dalfampridine sustained release tablets (trade name: Ampyra) was approved by the U.S. FDA in January 2010 to improve walking ability in patients with multiple sclerosis (MS). This is the first drug approved for this purpose, which enhances the conduction function of damaged nerves, but the precise mechanism of action is not clear. According to recent Acorda data released at the 63rd Annual Meeting of the American College of Neurology, regardless of the MS walking speed and MS-related overall disability